Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

Stanford Health Care

The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis.

The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis. Clinics in liver disease Yeoh, A., Wong, R., Singal, A. K. 2023; 27 (2): 413-427

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Disease spectrum varies from steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Currently, there are no approved medical therapies, and weight loss through lifestyle modifications remains a mainstay of therapy. Bariatric surgery is the most effective therapy for weight loss and has been shown to improve liver histology. Recently, endoscopic bariatric metabolic therapies have also emerged as effective treatments for patients with obesity and NAFLD. This review summarizes the role of bariatric surgery and endoscopic therapies in the management of patients with NAFLD.

View details for DOI 10.1016/j.cld.2023.01.009

View details for PubMedID 37024216